Search results for "PPRE"

showing 10 items of 2084 documents

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

2004

Abstract Purpose: No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved survival over any other in metastatic non-small cell lung cancer (NSCLC); however, the selection of patients according to key genetic characteristics can help to tailor chemotherapy. Ribonucleotide reductase subunit M1 (RRM1) is involved in DNA synthesis and repair and in gemcitabine metabolism, and the excision repair cross-complementing group 1 (ERCC1) gene has been related to cisplatin activity. Experimental Design: Patients were part of a large randomized trial carried out from September 1998 to July 2000, comparing gemcitabine/cisplatin versus gemcit…

AdultMaleOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsTime FactorsDNA RepairRibonucleoside Diphosphate Reductasemedicine.medical_treatmentAntineoplastic AgentsBiologyVinorelbineDeoxycytidineCarcinoma Non-Small-Cell LungInternal medicineRibonucleotide ReductasesmedicineHumansRNA MessengerLung cancerAgedCisplatinChemotherapyPredictive markerTumor Suppressor ProteinsDNAMiddle AgedEndonucleasesPrognosismedicine.diseaseGemcitabineChemotherapy regimenGemcitabineDNA-Binding ProteinsTreatment OutcomeOncologyFemaleCisplatinERCC1medicine.drugClinical Cancer Research
researchProduct

Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide

2009

Purpose To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. Patients and Methods A total of 41 adult patients (median Karnofsky performance status, 90%; median age, 56 years) were treated with preirradiation TMZ at 150 mg/m 2 (1 week on/1 week off), involved-field radiotherapy combined with concomitant low-dose TMZ (50 mg/m 2 ), maintenance TMZ starting at 150 mg/m 2 using a 1-week on/1-week off schedule, plus maintenance indomethacin (25 mg twice daily). Results The median follow-up interval was 21.7 months. Grade 4 hematologic toxicit…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentIndomethacinDisease-Free SurvivalDrug Administration ScheduleGermanyInternal medicineConfidence IntervalsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesKarnofsky Performance StatusAntineoplastic Agents AlkylatingDNA Modification MethylasesSurvival rateAgedChemotherapyRadiationTemozolomideBrain Neoplasmsbusiness.industryTumor Suppressor ProteinsAnti-Inflammatory Agents Non-SteroidalDNA MethylationMiddle AgedCombined Modality TherapyConfidence intervalSurgeryDacarbazineSurvival RateRegimenDNA Repair EnzymesOncologyConcomitantToxicityFemaleGlioblastomabusinessChemoradiotherapyFollow-Up Studiesmedicine.drugInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients…

2003

Patients with no prior chemotherapy and with advanced and progressive follicular lymphoma (FCL) or mantle cell lymphoma (MCL) were enrolled into a treatment protocol combining CHOP/rituximab-CHOP therapy with subsequent consolidation high-dose therapy (HDT) to evaluate the safety and feasibility of this treatment. Overall, 15 patients were enrolled and 13 patients completed the entire treatment protocol without major toxicities or increased infectious complications. One patient withdrew consent after achieving complete remission (CR) prior to HDT. One patient was taken off study with signs of disease progression after induction treatment. All patients showed stable engraftment after HDT. Re…

AdultMaleOncologymedicine.medical_specialtyLymphoma B-Cellmedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellCHOPTransplantation AutologousAntibodies Monoclonal Murine-Derivedimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCyclophosphamideImmunosuppression TherapyPeripheral Blood Stem Cell TransplantationTransplantationChemotherapybusiness.industryGraft SurvivalRemission InductionImmunityAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurvival AnalysisNon-Hodgkin's lymphomaSurgeryLymphomaTransplantationDoxorubicinVincristineFeasibility StudiesPrednisoneFemaleRadiotherapy AdjuvantMantle cell lymphomaRituximabRituximabbusinessmedicine.drugBone Marrow Transplantation
researchProduct

Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation

2016

Abstract Monitoring of minimal residual disease (MRD) or chimerism may help guide pre-emptive immunotherapy (IT) with a view to preventing relapse in childhood acute lymphoblastic leukemia (ALL) after transplantation. Patients with ALL who consecutively underwent transplantation in Frankfurt/Main, Germany between January 1, 2005 and July 1, 2014 were included in this retrospective study. Chimerism monitoring was performed in all, and MRD assessment was performed in 58 of 89 patients. IT was guided in 19 of 24 patients with mixed chimerism (MC) and MRD and by MRD only in another 4 patients with complete chimerism (CC). The 3-year probabilities of event-free survival (EFS) were .69 ± .06 for …

AdultMaleOncologymedicine.medical_specialtyNeoplasm ResidualAdolescentmedicine.medical_treatmenteducationDiseaseRelapse preventionChimerismYoung Adult03 medical and health sciences0302 clinical medicineRecurrenceGermanyInternal medicineSecondary PreventionHumansTransplantation HomologousMedicineddc:610ChildChildhood Acute Lymphoblastic LeukemiaImmunosuppression TherapyTransplantationbusiness.industryHematopoietic Stem Cell TransplantationRetrospective cohort studyHematologyImmunotherapyPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival AnalysisMinimal residual diseaseSurgeryTransplantationChild PreschoolLymphocyte Transfusion030220 oncology & carcinogenesisCohortFemaleImmunotherapybusiness030215 immunologyBiology of Blood and Marrow Transplantation
researchProduct

Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Trans…

2019

The current study evaluates the clinical effect of sirolimus exposure on the occurrence of cytomegalovirus (CMV) DNAemia necessitating preemptive antiviral therapy. A total of 167 consecutive recipients of reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT) who received sirolimus- and tacrolimus-based graft-versus-host disease (GVHD) prophylaxis and whose CMV serostatus was positive for donors and/or recipients were included in this multicenter retrospective study. A parametric model with consecutive sirolimus blood levels describing the time to CMV DNAemia-RAT was developed using NONMEM version 7.4. Overall, 122 of 167 patients (73%) were all…

AdultMaleOncologymedicine.medical_specialtyPremedicationmedicine.medical_treatmentCongenital cytomegalovirus infectionHematopoietic stem cell transplantationAntiviral AgentsAllogeneic hematopoietic stem cells transplantationMechanistic target of rapamycin inhibitorQuantitative PCR03 medical and health sciences0302 clinical medicineTime-to-event analysisInternal medicineHumansTransplantation HomologousMedicineCumulative incidenceCytomegalovirus diseaseSurvival analysisRetrospective StudiesSirolimusTransplantationDose-Response Relationship Drugbusiness.industryHazard ratioHematopoietic Stem Cell TransplantationPK/PDvirus diseasesRetrospective cohort studyHematologyMiddle Agedmedicine.diseaseCytomegalovirus infectionsurgical procedures operativeCytomegalovirus DNAemia030220 oncology & carcinogenesisSirolimusCytomegalovirus InfectionsPreemptive antiviral therapySirolimus exposureFemalebusinessSerostatusImmunosuppressive Agents030215 immunologymedicine.drug
researchProduct

PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy

2012

Soft tissue sarcomas are aggressive tumors representing <1% of all adult neoplasms. Aim of our study was to evaluate promyelocytic leukemia gene expression value as prognostic factor and as a factor predicting response to alkylating agents/antracycline-based first line therapy. One hundred eleven patients affected by locally advanced and metastatic soft tissue sarcoma were selected. PML expression was evaluated by immunohistochemical analysis in pathological samples and in the corresponding normal tissue from each case. PML immunohistochemical results were correlated with prognosis and with radiological response to alkylating agents/antracycline-based first line therapy. PML expression was …

AdultMaleOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical BiochemistryCellDown-RegulationSoft Tissue NeoplasmsPromyelocytic Leukemia ProteinLiposarcomaPleomorphic LiposarcomaYoung AdultPredictive Value of TestsInternal medicinemedicineHumansAnthracyclinesAntineoplastic Agents AlkylatingPathologicalAgedRetrospective StudiesAged 80 and overPMLbusiness.industryTumor Suppressor ProteinsSoft tissue sarcomaNuclear ProteinsSoft tissueSarcomaCell BiologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistrymedicine.anatomical_structuresoft tissue sarcomas; PMLDrug Resistance Neoplasmsoft tissue sarcomaImmunologyImmunohistochemistryFemaleSarcomabusinessTranscription Factors
researchProduct

Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective ana…

2014

Abstract Background Mitoxantrone is used on an off-label basis in primary progressive MS (PPMS). ABC -transporter-genotypes are associated with therapeutic response in relapsing/secondary progressive MS (RP/SPMS). Objective To evaluate potential pharmacogenetic response markers for mitoxantrone in PPMS. Methods 41 mitoxantrone-treated PPMS-patients, 155 mitoxantrone-treated RP/SPMS-patients and 43 PPMS-controls were retrospectively assessed for clinical therapy-response and in correlation with four single-nucleotide-polymorphisms in ABCB1 - and ABCG2 -genes. Results 53.7% PPMS-patients were mitoxantrone-responders, in comparison to 78.1% of RP/SPMS-patients (p = 0.039). There was no associa…

AdultMaleOncologymedicine.medical_specialtyTreatment responseATP Binding Cassette Transporter Subfamily Bmedicine.medical_treatmentImmunologyPrimary Progressive Multiple SclerosisPharmacologyInternal medicineGenotypeLack of efficacymedicineRetrospective analysisATP Binding Cassette Transporter Subfamily G Member 2HumansImmunology and AllergyRetrospective StudiesAnalgesicsMitoxantronebusiness.industryImmunosuppressionMiddle AgedMultiple Sclerosis Chronic ProgressiveNeoplasm Proteins3. Good healthNeurologyPharmacogeneticsATP-Binding Cassette TransportersFemaleNeurology (clinical)MitoxantronebusinessPharmacogeneticsmedicine.drugJournal of Neuroimmunology
researchProduct

Somatic loss of an EXT2 gene mutation during malignant progression in a patient with hereditary multiple osteochondromas

2015

Multiple osteochondromas (MO) is an autosomal-dominant skeletal disorder caused by mutations in the exostosin-1 ( EXT1 ) or exostosin-2 ( EXT2 ) genes. In this study, we report the analysis of the mutational status of the EXT2 gene in tumor samples derived from a patient affected by hereditary MO, documenting the somatic loss of the germline mutation in a giant chondrosarcoma and in a rapidly growing osteochondroma. The sequencing of all exons and exon–intron junctions of the EXT1 and EXT2 genes from blood DNA of the proband did not reveal any mutation in the EXT1 gene but did demonstrate the presence of the transition point mutation c.67C > T in the EXT2 gene, determining the introduction …

AdultMaleOsteochondromaCancer ResearchMultiple osteochondromaSettore MED/06 - Oncologia MedicaChondrosarcomaLoss of HeterozygositySettore BIO/11 - Biologia MolecolareBone NeoplasmsGene mutationBiologyN-Acetylglucosaminyltransferasesmedicine.disease_causeGermlineLoss of heterozygosityGermline mutationGeneticChondrosarcoma; Hereditary cancer; Hereditary multiple osteochondromas; Tumor suppressor gene; Molecular Biology; Genetics; Cancer ResearchSkeletal disorderGeneticsmedicineHumansTumor suppressor geneHereditary multiple osteochondromaMolecular BiologyGeneticsMutationChromosomes Human Pair 11DNA Neoplasmmedicine.diseaseHereditary cancerSettore MED/18 - Chirurgia GeneraleSettore MED/03 - Genetica MedicaMutationDisease ProgressionCancer Genetics
researchProduct

P16INK4A and p15INK4B gene alteration associated with oxidative stress in renal cell carcinomas after the chernobyl accident (pilot study).

2002

Our study was undertaken to better understand the role of G1/S transition abnormalities in the malignant progression of renal cell carcinomas (RCCs), exposed to long-term low doses of ionizing radiation (IR), from patients living in radiocontaminated areas of the Ukraine after the Chernobyl accident. We studied p16 and p15 gene alteration in association with oxidative stress markers, including inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX2). We analyzed 88 samples collected from 22 patients with RCCs and with different exposure to IR. Homozygous deletion of the p16 and p15 genes, as well as hypermethylation of the 5CpG island in the promoter region of the same genes, were…

AdultMalePathologymedicine.medical_specialtyAdolescentCellCell Cycle ProteinsPilot Projectsmedicine.disease_causePolymerase Chain ReactionPathology and Forensic MedicineImmunoenzyme TechniquesCarcinomamedicineBiomarkers TumorHumansMolecular BiologyCarcinoma Renal CellCyclin-Dependent Kinase Inhibitor p16AgedCyclin-Dependent Kinase Inhibitor p15Neoplasm Stagingbiologybusiness.industryTumor Suppressor ProteinsPromoterCell BiologyDNA NeoplasmDNA MethylationMiddle Agedmedicine.diseaseKidney NeoplasmsNitric oxide synthaseOxidative Stressmedicine.anatomical_structureDNA methylationbiology.proteinImmunohistochemistryHistopathologyFemalebusinessRadioactive Hazard ReleaseUkraineOxidative stressPower PlantsDiagnostic molecular pathology : the American journal of surgical pathology, part B
researchProduct

Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis.

1996

Abstract Background/Aims: Autoimmune hepatitis, primary biliary cirrhosis and primary sclerosing cholangitis are chronic liver diseases with probable autoimmune background. Overlapping features have been described for primary biliary cirrhosis and autoimmune hepatitis. In contrast, there have been only a few case reports on an overlap of autoimmune hepatitis and primary sclerosing cholangitis. Methods: We describe three male patients with clinical and histological overlapping features of primary sclerosing cholangitis and autoimmune hepatitis. Results: All initially asymptomatic patients had elevated levels of aminotransferases, alkaline phosphatase, γ-glutamyltranspeptidase and IgG. Anti-n…

AdultMalePathologymedicine.medical_specialtyCirrhosisAdolescentBiopsyCholangitis SclerosingAutoimmune hepatitisGastroenterologyPrimary sclerosing cholangitisAutoimmune DiseasesDiagnosis DifferentialPrimary biliary cirrhosisInternal medicinemedicineHumansTransaminasesHepatitis ChronicHepatitisAutoimmune diseaseCholangiopancreatography Endoscopic RetrogradeHepatologyBile ductbusiness.industryOverlap syndromeSyndromemedicine.diseasemedicine.anatomical_structureAntibodies AntinuclearImmunoglobulin GbusinessImmunosuppressive AgentsFollow-Up StudiesJournal of hepatology
researchProduct